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ABSTRACT 
The insight that stem- and progenitor-cells contribute to replacement of nerve cells in the adult 
central nervous system is the basis of modern therapies for structural brain repair. Their goal is to 
protect, support and stimulate endogenous stem cells in areas affected by disease and to replace 
lost cells by transplanting in vitro generated, tailored nerve cells.  
In the present thesis growth factors and signaling molecules were investigated for their po-
tential to direct stem- and neural progenitor- cells towards neuronal cell fate. Involved signaling 
pathways were characterized and candidate molecules identified that might be beneficial for cell-
based therapies in Parkinson’s disease. 
Results show that Bone Morphogenetic Proteins (BMPs) and Growth Differentiation Fac-
tors increase astroglial differentiation while inhibiting oligodendrocyte maturation in rat embry-
onic mesencephalic culture. None of the factors protect dopaminergic neurons against oxidative 
radicals in vitro. BMP5, 6 and 7, however, promote dopaminergic differentiation by directly tar-
geting the neuronal cell population. 
 In cultures of adult rat hippocampus-derived progenitors (AHPs), endogenous BMPs were 
found to increase undesired astroglial differentiation via the BMP type I receptors ALK6 and 
ALK2. By viral transduction of dominant negative ALK2 or ALK6, respectively, BMP signaling 
was blocked in order to inhibit astroglial cell differentiation. Indeed, the expression of glial fibril-
lary acidic protein (GFAP), a marker for astrocytes, decreased. The number of oligodendrocytes 
increased and neurons were not affected. However, the strategy proved impractical since it in-
duced cell death. RT-PCR results indicate that only the ALK6, but not the ALK2 receptor, is dy-
namically regulated in these cultures, suggesting that ALK6 is mainly responsible for glial differ-
entiation and survival of AHPs. 
Apoptosis signal-regulating kinase-1 is a ubiquitously expressed enzyme involved in apop-
tosis. Overexpression of its constitutively active form induced neuronal differentiation in AHP 
culture. At the same time GFAP expression was inhibited. The effect is mediated via p38 mito-
gen-activated protein kinase and via inhibition of GFAP promoter activity. 
In order to generate transplantable dopaminergic neurons, human embryonic stem cells 
(hESCs) were cocultured with the stromal cell line PA6, known to instruct mouse and primate 
ESCs towards dopaminergic cell fate. About 11% of hESCs developed into tyrosine hydroxylase-
positive (TH-pos) neurons with CNS identity. The hESC-derived neurons displayed action poten-
tial in vitro. However, they did not induce behavioral recovery after transplantation to the 6-hy-
droxydopamine -lesioned rat striatum. Extended differentiation time on PA6 in vitro decreased 
the risk for teratoma formation after transplantation, but did not elevate the low number of TH-
pos neurons in the graft. 
In conclusion, certain BMPs as well as ASK1 have been identified as molecules that in-
crease neuronal differentiation. Their putative role in experimental CNS cell therapies is dis-
cussed. At the moment, however, the gap between experimental systems and biological reality is 
difficult to overcome. Further investigations that are necessary to reduce safety concerns in cell-
based treatment strategies are outlined.    
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